The group with adverse outcomes exhibited significantly higher rates of diabetes, heart retransplants, pretransplant dialysis, increased right heart pressures, and elevated BNP or N terminal pro-BNP levels, alongside lower eGFRs. This evidence concerns the gene NPPB and diabetes mellitus.